Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 by Atorvastatin for Reducing the Risk of Longstanding Ulcerative Colitis-Associated Cancer A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 b ...